Century Therapeutics Inc
Company Profile
Business description
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.
Contact
25 N 38th Street
11th Floor
PhiladelphiaPA19104
USAT: +1 267 817-5790
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
165
Stocks News & Analysis
stocks
Australia has the highest dividend yields in the world, so why the endless chase for even higher yields?
stocks
These 2 ASX stocks look materially overvalued after earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,804.20 | 4.60 | 0.05% |
CAC 40 | 8,164.11 | 121.92 | 1.52% |
DAX 40 | 22,612.02 | 463.99 | 2.09% |
Dow JONES (US) | 44,489.20 | 120.64 | 0.27% |
FTSE 100 | 8,764.72 | 42.72 | -0.49% |
HKSE | 21,814.37 | 43.55 | -0.20% |
NASDAQ | 19,815.22 | 165.27 | 0.84% |
Nikkei 225 | 39,461.47 | 497.77 | 1.28% |
NZX 50 Index | 12,905.98 | 7.97 | -0.06% |
S&P 500 | 6,083.62 | 31.65 | 0.52% |
S&P/ASX 200 | 8,540.00 | 4.70 | 0.06% |
SSE Composite Index | 3,332.48 | 13.90 | -0.42% |